- Home
- TBPH vs SIBN Comparison
TBPH vs SIBN Comparison
Compare TBPH & SIBN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TBPH
- SIBN
- Stock Information
- Founded
- TBPH 2013
- SIBN 2008
- Country
- TBPH United States
- SIBN United States
- Employees
- TBPH N/A
- SIBN N/A
- Industry
- TBPH Biotechnology: Pharmaceutical Preparations
- SIBN Medical/Dental Instruments
- Sector
- TBPH Health Care
- SIBN Health Care
- Exchange
- TBPH Nasdaq
- SIBN Nasdaq
- Market Cap
- TBPH 464.5M
- SIBN N/A
- IPO Year
- TBPH N/A
- SIBN 2018
- Fundamental
- Price
- TBPH $9.01
- SIBN $14.36
- Analyst Decision
- TBPH Buy
- SIBN Strong Buy
- Analyst Count
- TBPH 4
- SIBN 6
- Target Price
- TBPH $13.75
- SIBN $24.50
- AVG Volume (30 Days)
- TBPH 192.5K
- SIBN 333.5K
- Earning Date
- TBPH 05-12-2025
- SIBN 05-05-2025
- Dividend Yield
- TBPH N/A
- SIBN N/A
- EPS Growth
- TBPH N/A
- SIBN N/A
- EPS
- TBPH N/A
- SIBN N/A
- Revenue
- TBPH $64,381,000.00
- SIBN $167,178,000.00
- Revenue This Year
- TBPH $51.09
- SIBN $18.52
- Revenue Next Year
- TBPH N/A
- SIBN $16.39
- P/E Ratio
- TBPH N/A
- SIBN N/A
- Revenue Growth
- TBPH 12.12
- SIBN 20.37
- 52 Week Low
- TBPH $7.44
- SIBN $11.70
- 52 Week High
- TBPH $10.90
- SIBN $19.16
- Technical
- Relative Strength Index (RSI)
- TBPH 41.82
- SIBN 38.91
- Support Level
- TBPH $8.72
- SIBN $13.65
- Resistance Level
- TBPH $9.55
- SIBN $15.40
- Average True Range (ATR)
- TBPH 0.25
- SIBN 0.56
- MACD
- TBPH -0.04
- SIBN -0.03
- Stochastic Oscillator
- TBPH 34.94
- SIBN 40.57
About TBPH Theravance Biopharma Inc.
Theravance Biopharma Inc is a diversified biopharmaceutical company focused on the discovery, development, and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small-molecule drugs designed to better meet patient needs. Its research is focused on the areas of inflammation and immunology. The firm applies organ-selective expertise to target disease biologically, to discover and develop medicines that may expand the therapeutic index with the goal of maximizing efficacy and limiting systemic side effects. The company develops lung-selective medicines to treat respiratory disease, including FDA-approved YUPELRI (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD).